


In the claims:

1. (Currently Amended) A compound of formula (I):



(I)

wherein:

R¹ is H, CH₂R⁵ or COR⁶;

R² is alkyl C₁₋₆ or alkenyl C₁₋₆, optionally substituted by one or more groups selected from alkyl C₁₋₆ and halogen;

R³ is cycloalkyl C₃₋₈, optionally substituted by R⁷;

R⁴ is H or alkyl C₁₋₆, optionally substituted by one or more halogens;

R⁵ is H, phenyl or alkyl C₁₋₆, optionally substituted by halogen, OR⁸, and phenyl;


R⁶ is OR⁹ or alkyl C₁₋₆, optionally substituted by one or more groups selected from halogen, OR¹⁰, and phenyl;

R⁷ is phenyl, optionally substituted by one or more groups selected from alkyl C₁₋₆, halogen, and OR⁸;

R⁸, R⁹ and R¹⁰, are independently H or alkyl C₁₋₆, optionally substituted by one or more groups selected from halogen or alkyl C₁₋₆;

or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.

2. (Previously Presented) A compound of according to claim 1 which is:



(Ia)

where R^1 , R^2 , R^3 and R^4 are as defined in claim 1.

3. (Currently Amended) A compound according to claim 1 or 2 in which R^3 is
wherein:

R^7 is phenyl, optionally substituted by one or more groups selected from alkyl C₁₋₆, halogen, and OR⁸;

R^8 is independently H or alkyl C₁₋₆, optionally substituted by one or more groups selected from halogen or alkyl C₁₋₆.

~~where R^7 is as defined in claim 1.~~

4. (Currently Amended) A compound according to ~~any one of~~ claims 1 or 2 to 3 in which R^1 is H, CH₂Ph, CH₂CH₂OH, or CO₂tBu.

5. (Currently Amended) A compound according to ~~any one of~~ claims 1 or 2 to 4 in which R^2 is n-Pr.

6. (Currently Amended) A compound according to ~~any one of~~ claims 1 ~~or 2 to 5~~ in which R³ is cycloalkyl C₃₋₈ substituted by phenyl.

7. (Currently Amended) A compound according to ~~any one of~~ claims 1 ~~or 2 to 6~~ in which R⁴ is H or methyl.

8. (Currently Amended) A compound according to claim 1 which is:

[3R-[3 α ,4 β (1R*,2S*)]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol;

[3S-[3 α ,4 β (1S*,2R*)]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester;

[3S-[3 α ,4 β (1R*, 2S*)]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester;

[3S-[3 α ,4 β (1S*,2R*)]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol;

[3R-[3 α ,4 β (1R*,2S*)]-4-[7-[N-Methyl-N-(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol;

[3R-[3 α ,4 β (1R*,2S*)]-1-Hydroxyethyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol;

[3R-[3 α ,4 β (1R*,2S*)]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-(phenylmethyl)-3-pyrrolidinol;

[3R-[3 α , 4 β (1R*,2S*)]-1-Acetyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol;

or or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.

9. **(Currently Amended)** A pharmaceutical composition comprising a compound according to any one of claims 1 or 2 to 8 in combination with a pharmaceutically acceptable diluent, adjuvant adjuvant or carrier.


10-16. **(Cancelled)**

17. **(Currently Amended)** A method of treatment ~~or prevention~~ of a platelet aggregation disorder which comprises administering to a person suffering from or susceptible to such a disorder a therapeutically effective amount of compound according to any one of claims 1 or 2 to 8.

18. **(Currently Amended)** A method of treatment ~~or prevention~~ of myocardial infarction, thrombotic stroke, transient ischaemic attacks, and/or peripheral vascular disease, which comprises administering to a person suffering from or susceptible to such a disorder a therapeutically effective amount of a compound according to any one of claims 1 or 2 to 8.

19. **(Currently Amended)** A method of treatment ~~or prevention~~ of unstable or stable angina, which comprises administering to a person suffering from or susceptible to such a disorder a therapeutically effective amount of a compound according to any one of claims 1 or 2 to 8.

20. (Previously Presented) A process for the preparation of a compound of formula (I), where R¹ is H, which comprises reacting a compound of formula (II)



(II)

wherein R² is as defined in claim 1 and P is a protecting group, with R³R⁴NH, wherein R³ and R⁴ are as defined in claim 1, and a base and optionally thereafter removing any protecting groups.

21. (Cancelled)